What it's for (Indications)
- Eplerenone is a selective aldosterone receptor antagonist primarily indicated for the treatment of hypertension and heart failure post-myocardial infarction (MI).
- For hypertension, it is used to lower blood pressure, either alone or in combination with other antihypertensive agents, particularly in patients who cannot tolerate or achieve adequate blood pressure control with other therapies.
- In heart failure, specifically in patients with left ventricular systolic dysfunction and evidence of heart failure (e.
- g.
- , LVEF ≤40%) following an acute MI, eplerenone is used to improve survival and reduce the risk of hospitalization for cardiovascular events.
- Its efficacy in these settings is attributed to its ability to block the detrimental effects of aldosterone on the heart and vasculature, which include fibrosis, inflammation, and remodeling, thereby mitigating disease progression and improving patient outcomes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of eplerenone varies depending on the specific indication and patient's clinical status. For hypertension, the usual starting dose is 50 mg orally once daily. If blood pressure control is inadequate after four weeks, the dose may be increased to 100 mg once daily. For heart failure post-myocardial infarction, the recommended initial dose is 25 mg orally once daily, which can be titrated up to a target dose of 50 mg once daily, preferably within four weeks, based on serum potassium levels and renal function. Dosing adjustments are crucial and must be guided by regular monitoring of serum potassium and creatinine levels, especially during initiation and titration, to mitigate the risk of hyperkalemia. Patients with moderate renal impairment or those concomitantly receiving CYP3A4 inhibitors may require dose adjustments or more frequent monitoring and should be managed by a clinician. |
Safety & Warnings
Common Side Effects
- Eplerenone, while generally well-tolerated, can lead to several side effects.
- The most clinically significant and potentially serious adverse effect is hyperkalemia, which manifests as elevated serum potassium levels and can lead to life-threatening cardiac arrhythmias.
- Other common side effects include dizziness, fatigue, headache, diarrhea, abdominal pain, and cough.
- Less common but notable adverse effects include renal impairment (evidenced by increased serum creatinine), hypotension, and asthenia.
- While rare, endocrine-related side effects such as gynecomastia and breast pain have been reported, although these are considerably less frequent compared to non-selective mineralocorticoid receptor antagonists like spironolactone due to eplerenone's higher selectivity.
- Patients should be advised to report any concerning symptoms or adverse reactions to their healthcare provider promptly for evaluation.
Serious Warnings
- Black Box Warning: Eplerenone does not carry a formal FDA-mandated Black Box Warning. However, due to the significant and potentially life-threatening risk of hyperkalemia associated with its use, particularly in vulnerable patient populations, a prominent 'Serious Warnings' section is essential. **Serious Warnings: Hyperkalemia Risk** Eplerenone can cause severe and sometimes fatal hyperkalemia. This risk is notably elevated in patients with impaired renal function, pre-existing hyperkalemia, diabetes mellitus, and in those receiving concomitant medications that increase potassium levels, such as potassium-sparing diuretics, potassium supplements, or strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir). Meticulous monitoring of serum potassium and renal function (creatinine) is mandatory: before initiating therapy, within the first week of treatment, during dose titrations, and periodically thereafter. Dose adjustments or discontinuation may be required based on potassium levels and renal function. Patients must be educated about the signs and symptoms of hyperkalemia (e.g., muscle weakness, fatigue, paresthesias, cardiac irregularities) and advised to seek immediate medical attention if they experience such symptoms.
- Several critical warnings are associated with eplerenone use.
- The most prominent is the risk of developing hyperkalemia, which can be severe and potentially fatal, particularly in patients with impaired renal function, elevated baseline serum potassium levels, or those receiving concomitant potassium-sparing diuretics, potassium supplements, or strong CYP3A4 inhibitors.
- Close monitoring of serum potassium and renal function (serum creatinine) is imperative before initiating therapy, within the first week, and regularly thereafter, especially during dose adjustments or intercurrent illness.
- Eplerenone should be used with caution in patients with moderate hepatic impairment, as systemic exposure may be increased.
- Furthermore, concomitant use with strong CYP3A4 inhibitors is contraindicated due to a significant increase in eplerenone exposure and associated risk of hyperkalemia.
- Patients should be educated on the symptoms of hyperkalemia and the importance of adhering to prescribed monitoring schedules.
How it Works (Mechanism of Action)
Eplerenone exerts its therapeutic effects by acting as a highly selective antagonist of the mineralocorticoid receptor (MR). Aldosterone, a potent mineralocorticoid hormone, binds to these receptors in various tissues, including the kidneys, heart, blood vessels, and brain, leading to diverse physiological effects such as sodium and water retention, potassium excretion, and activation of pro-fibrotic and pro-inflammatory pathways. By selectively blocking aldosterone's binding to the MR, eplerenone counteracts these detrimental effects. In the kidneys, it promotes natriuresis (sodium excretion) and diuresis, while conserving potassium. In the cardiovascular system, its MR blockade helps to reduce cardiac remodeling, fibrosis, and inflammation, thereby improving cardiovascular outcomes in conditions like heart failure and reducing blood pressure in hypertension. Its high selectivity for the MR distinguishes it from non-selective antagonists like spironolactone, which also interact with androgen and progesterone receptors, leading to a reduced incidence of associated endocrine side effects.